Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | GRM5 | P41594 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30707788 | 1.00 | KCNH2 (0.61) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL29868474 | 0.88 | KCNH2 (0.52) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL31279173 | 0.87 | FFAR1 (0.57) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL1920654 | 0.87 | FFAR1 (0.57) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL4867351 | 0.86 | KCNH2 (0.50) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL28365711 | 0.86 | KCNH2 (0.50) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL29428997 | 0.85 | ALDH1A1 (0.59) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL29120757 | 0.85 | KCNH2 (0.50) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL2462120 | 0.84 | KCNH2 (0.53) | KCNH2GRM5TSHRLMNAPTGDR2 | |
| SCHEMBL1610606 | 0.84 | KCNH2 (0.48) | KCNH2GRM5TSHRLMNAPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285454-A | Synthesis method of indole derivative and benzodipyrrole derivative | 南京邮电大学 | 2023-12-26 | — | — | CN | claimed |
| CN-110028394-B | Synthetic method of indanone and derivatives thereof | 南京邮电大学 | 2021-09-17 | — | — | CN | claimed |
| US-7595413-B2 | Phosphine-substituted vinyl containing metallocene catalyst, preparation process and the application of the same | PETROCHINA COMPANY LIMITED (CN) | 2009-09-29 | — | — | US | claimed |
| US-20080194854-A1 | Phosphine-substituted vinyl containing metallocene catlyst, preparation process and the application of the same | PETROCHINA COMPANY LIMITED (CN) | 2008-08-14 | — | — | US | claimed |
| CN-117285454-A | Synthesis method of indole derivative and benzodipyrrole derivative | 南京邮电大学 | 2023-12-26 | — | — | CN | disclosed |
| CN-110028394-B | Synthetic method of indanone and derivatives thereof | 南京邮电大学 | 2021-09-17 | — | — | CN | disclosed |
| US-7595413-B2 | Phosphine-substituted vinyl containing metallocene catalyst, preparation process and the application of the same | PETROCHINA COMPANY LIMITED (CN) | 2009-09-29 | — | — | US | disclosed |
| US-20080194854-A1 | Phosphine-substituted vinyl containing metallocene catlyst, preparation process and the application of the same | PETROCHINA COMPANY LIMITED (CN) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194854-A1 | Phosphine-substituted vinyl containing metallocene catlyst, preparation process and the application of the same | PI4K2B, PI4K2A, CPNE4 | KCNH2 1433/4885GRM5 2950/4885TSHR 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.